Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 332 followers
Latest posts
Last updated about 14 hours ago
Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised
about 14 hours ago
Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation...
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 31, Status: Authorised
about 14 hours ago
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation...
Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 6, Status: Authorised
about 15 hours ago
Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation...
SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)
about 16 hours ago
SME info day - navigating EMA support: From development to market authorisation...
Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised
about 16 hours ago
Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation...
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised
about 16 hours ago
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation...
Emergency Task Force (ETF) recommendations
about 17 hours ago
Emergency Task Force (ETF) recommendations
ETF recommends updating COVID-19 vaccines to target XFG variant
about 17 hours ago
ETF recommends updating COVID-19 vaccines to target XFG variant
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027
about 17 hours ago
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for...
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
about 18 hours ago
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific...
List of centrally authorised products with safety-related changes to the product information
about 18 hours ago
List of centrally authorised products with safety-related changes to the product information